Evaluating response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is crucial in non-small cell lung cancer (NSCLC) patients with brain metastases (BM).
To explore values of multi-sequence MRI in early assessing response to EGFR-TKIs in non-small cell lung cancer (NSCLC) patients with BM.
